Inclusion Criteria:

          1. Participants must have histologically confirmed salivary gland carcinoma (any
             histologic subtype, including ACC) with evidence of recurrent, metastatic or advanced,
             unresectable disease.

          2. Willing to provide tumor tissue from a diagnostic biopsy or prior surgery.

          3. Age 18 years or older

          4. ECOG performance status 0-2 (see Appendix A)

          5. Participant must have organ and marrow function as defined below within 14 days prior
             to study registration:

               -  leukocytes ≥ 3,000/mcL

               -  absolute neutrophil count ≥ 500/mcL

               -  hemoglobin ≥ 8.5 g/dL

               -  platelets ≥ 75,000/mcL

               -  total bilirubin ≤ 2.0 g/dL

               -  AST(SGOT)/ALT(SGPT) ≤ 2.5× institutional upper limit of normal

               -  creatinine within normal institutional limits OR

               -  creatinine clearance ≥50 mL/min/1.73 m2 for participants with creatinine levels
                  above institutional normal

          6. Participants must have documentation of a new or progressive lesion on a radiologic
             imaging study performed within 12 months prior to study registration (progression of
             disease over any interval is allowed) and/or new or worsening disease-related symptoms
             within 12 months prior to study registration.

          7. Participants must have at least one RECIST v1.1 measurable non-CNS based lesion.

          8. Prior systemic therapy: At least 2 weeks must have elapsed since the end of prior
             chemotherapy, biological agents (3 weeks for anti-cancer monoclonal antibody
             containing regimens) or any investigational drug product, with adequate recovery of
             treatment-related toxicity to NCI CTCAE Version 5.0 grade ≤1 (or tolerable grade 2) or
             back to baseline (except for alopecia or neuropathy). Any number of prior therapies
             for recurrent/metastatic SGC are permitted (including prior carboplatin exposure).

          9. Ability to understand and the willingness to sign a written informed consent document.

         10. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to
             the start of study treatment.

         11. Men who are sexually active with WOCBP must agree to use any contraceptive method with
             a failure rate of less than 1% per year. Men who are sexually active with WOCBP will
             be instructed to adhere to contraception for a period of 90 days after the last dose
             of investigational product.

        Exclusion Criteria:

          1. Metastatic disease impinging on the spinal cord or threatening spinal cord
             compression. Patients that have had previous treatment of disease with impinging on
             the cord with either surgery or radiotherapy with clinical or radiographic evidence of
             response or stability are eligible.

          2. Participant has known active central nervous system (CNS) metastases and/or
             carcinomatous meningitis. Subjects with previously treated brain metastases may
             participate provided they are stable (without evidence of progression by imaging for
             at least four weeks prior to the first dose of trial treatment), and have no evidence
             of new or enlarging brain metastases.

          3. Concurrent administration of other cancer specific therapy or investigational agents
             during the course of this study is not allowed.

          4. Uncontrolled intercurrent illness including but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
             arrhythmia.

          5. Pregnant or lactating women.

          6. Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include: basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer, and
             low-risk prostate adenocarcinoma being managed with active surveillance. A history of
             another separate malignancy in remission without evidence of active disease in the
             last 2 years is permitted.